Cargando…

The TOUCH program and natalizumab: Fundamental flaw in patient protection

Many drugs have been approved by the Food and Drug Administration (FDA) since 1993 for treatment of relapsing forms of multiple sclerosis (MS). One such drug is natalizumab (Tysabri, Biogen Idec and Elan pharmaceuticals) which has enjoyed great success in the management of MS since its re-introducti...

Descripción completa

Detalles Bibliográficos
Autor principal: Avasarala, Jagannadha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000Research 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4837976/
https://www.ncbi.nlm.nih.gov/pubmed/27134725
http://dx.doi.org/10.12688/f1000research.7513.3